Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Share:
Related GSK
GlaxoSmithKline Expands Its Portfolio Of Medicines In The US For Patients With Asthma And COPD
Benzinga's Weekend M&A Chatter
Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog (Zacks)
Related THRX
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Barron's Recap: Ready To Wear?
9 Hot Healthcare Dividend Dogs Dog 12% To 46% December Upsides (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters